Matthew Nix is a principal scientist in the Immunology Group focused on driving the early-stage development of Cartography’s pipeline of novel CAR-T therapies. Before joining Cartography, Matt conducted research at UCSF in the department of laboratory medicine where he developed a new CAR-T therapy for difficult to treat pediatric leukemia, which is now poised to head to clinical trials at UCSF. He is also an Assistant Adjunct Professor at UCSF, and when he’s not daydreaming about cell therapies and synthetic biology, he likes to hike and camp with his wife, two kids, and his super-mutt Milo.
- Cartography Biosciences Expands Leadership Team with Appointment of Dan Rock, Ph.D., as Chief Scientific Officer to Advance Novel Oncology Programs into Clinic
- Cartography Biosciences and Nested Therapeutics: Diamonds in the rough
- Cartography Biosciences Expands Scientific Advisory Board with Leading Antibody and Bi-specific Experts
- Cartography Biosciences Co-Founder and Chief Executive Officer Kevin Parker, Ph.D., Earns Spot on Endpoints News’ 20 Under 40 List
- Cartography Biosciences Appoints Industry Veteran as Chief Administrative and Legal Officer
No comments to show.